NMRA stock icon

Neumora Therapeutics
NMRA

$11.41
9.94%

Market Cap: $1.83B

 

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Employees: 108

0
Funds holding %
of 6,710 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

258% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 12

127% more call options, than puts

Call options by funds: $1.81M | Put options by funds: $797K

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

8% more funds holding

Funds holding: 86 [Q1] → 93 (+7) [Q2]

7.13% more ownership

Funds ownership: 33.08% [Q1] → 40.21% (+7.13%) [Q2]

13% less capital invested

Capital invested by funds: $724M [Q1] → $630M (-$93M) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$20
75%
upside
Avg. target
$24
108%
upside
High target
$29
154%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Brian Abrahams
56% 1-year accuracy
40 / 72 met price target
154%upside
$29
Outperform
Reiterated
4 Sept 2024
Needham
Ami Fadia
52% 1-year accuracy
68 / 130 met price target
102%upside
$23
Buy
Reiterated
7 Aug 2024
Needham
Ami Fadia
52% 1-year accuracy
68 / 130 met price target
102%upside
$23
Buy
Initiated
22 Jul 2024
Mizuho
Graig Suvannavejh
52% 1-year accuracy
15 / 29 met price target
75%upside
$20
Outperform
Initiated
8 Jul 2024

Financial journalist opinion